The Trump administration's recent decision to impose new tariffs on pharmaceuticals is expected to impact supply chain dynamics within the healthcare sector.
In conjunction with these tariffs, the administration has rolled back levies on some metals, which may alter the cost structure for manufacturers reliant on these materials.
This dual approach could lead to shifts in operational strategies among pharmaceutical companies and metal suppliers as they adapt to the changing duty landscape.